Australian Medical Technology Company Opens Minnesota Office
PR Newswire - Wed Jun 08, 10:00AM CDT
Australian-based medical technology company ImpediMed Limited (ASX: IPD) announced today the opening of a regional office in Bloomington, Minn., and the addition of two Minnesota medical technology veterans - Ann Holder and Jack Cosentino - to its executive leadership team.
MDT: 84.26 (-0.33), IPD: 34.85 (-0.40)
ImpediMed Signs Five Year, Multi-Location Clinical Trial Agreement with Mayo Clinic
PR Newswire - Tue May 31, 9:15AM CDT
ImpediMed Limited (ASX: IPD) announced today that it has entered into a five year master clinical trial agreement with Mayo Clinic to explore additional indications for its fluid status and body composition monitoring technology.
IPD: 34.85 (-0.40)
ImpediMed completes A$75 million Private Placement
PR Newswire - Tue Mar 22, 10:07AM CDT
ImpediMed Limited (ASX: IPD), a global provider of medical technology to measure, monitor and manage fluid status in patients, announced the completion of its recent capital raising activity, raising a total of A$75.1 million before costs.
IPD: 34.85 (-0.40)
ImpediMed Establishes Medical Advisory Board for Chronic Heart Failure
PR Newswire - Mon Jan 11, 11:30AM CST
ImpediMed Limited (ASX: IPD), a global provider of medical technology to measure, monitor and manage fluid status and body composition, announced today that it has entered into agreements to establish a Medical Advisory Board to advise the Company on the design of clinical trials for the use of bioimpedance spectroscopy (BIS) in fluid detection for chronic heart failure patients.
IPD: 34.85 (-0.40)
ImpediMed Announces U.S. Commercial Launch of L-Dex® System for Assessment of Lymphedema in Cancer Survivors
PR Newswire - Thu Jan 07, 12:51PM CST
ImpediMed Limited (ASX: IPD), a global provider of medical technology to measure, monitor and manage fluid status in patients, has announced the U.S. commercial launch of its L-Dex® system to aid in the clinical assessment of lymphedema.
IPD: 34.85 (-0.40)